🇺🇸 FDA
Patent

US 10561724

Live attenuated virus vaccines for La Crosse virus and other bunyaviridae

granted A61KA61K2039/5252A61K2039/5254

Quick answer

US patent 10561724 (Live attenuated virus vaccines for La Crosse virus and other bunyaviridae) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/5252, A61K2039/5254, A61K39/00, A61K39/12